Vicarious Surgical Advances Cost Restructuring and Nasdaq Relisting Strategy While Progressing Toward Surgical Robot Milestone
Robotics surgery developer cuts projected 2026 cash burn to $19M, applies for Nasdaq Capital Market listing, and targets system design freeze for its next-generation surgical platform by year-end.